Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Yongping Yu was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Feb 04
Full year 2025 earnings released: US$8.06 loss per share (vs US$627 loss in FY 2024) Full year 2025 results: US$8.06 loss per share (improved from US$627 loss in FY 2024). Revenue: US$17.9m (down 22% from FY 2024). Net loss: US$3.67m (loss narrowed 58% from FY 2024). New Risk • Jan 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Market cap is less than US$10m (US$2.54m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). New Risk • Oct 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 60% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Market cap is less than US$10m (US$2.91m market cap). Aankondiging • Jul 30
Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025 Universe Pharmaceuticals INC, Annual General Meeting, Aug 26, 2025, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and technology, development zone, jiangxi 343100., jian China Reported Earnings • Jul 07
First half 2025 earnings released First half 2025 results: US$9.44 loss per share. Revenue: US$9.15m (down 29% from 1H 2024). Net loss: US$3.28m (loss narrowed 75% from 1H 2024). Reported Earnings • May 01
Full year 2024 earnings released Full year 2024 results: US$627 loss per share. Revenue: US$23.0m (down 29% from FY 2023). Net loss: US$8.73m (loss widened 42% from FY 2023). Aankondiging • Feb 26
Universe Pharmaceuticals Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report Universe Pharmaceuticals INC (the “Company”) announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the “Form 20-F”) and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Company is before a Hearings Panel for its failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension of the Company’s securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that date. The Company is working on completing and filing the delayed Form 20-F. This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. Aankondiging • Feb 04
Universe Pharmaceuticals Receives Nasdaq Delisting Notice Subject to Hearing Request Universe Pharmaceuticals INC announced that the Company received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company’s ordinary shares from The Nasdaq Capital Market (the “Delisting Determination”), because the bid price of the Company’s listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the “Rule”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Rule. However, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split on November 18, 2024, or within the prior one-year period. The Company was provided until February 5, 2025 to request an appeal of the Delisting Determination to the hearing panel. The Company intends to request such hearing to appeal the Delisting Determination before that date, which will stay the suspension of its securities from the date of the request, during which time such securities will continue to be listed on The Nasdaq Capital Market. If the Company fails to request an appeal of the Delisting Determination by February 5, 2025, trading of the Company’s ordinary shares will be suspended at the opening of business on February 7, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company is considering all potential options available to it to regain compliance with the aforementioned rules, including seeking shareholders’ approval for a reverse stock split. Aankondiging • Jan 28
Universe Pharmaceuticals INC announced delayed 20-F filing On 01/27/2025, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC. Aankondiging • Dec 12
Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million. Universe Pharmaceuticals INC has completed a Follow-on Equity Offering in the amount of $14.981638 million.
Security Name: Ordinary Share
Security Type: Common Stock
Securities Offered: 388,000
Price\Range: $0.8
Discount Per Security: $0.056
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 18,362,000
Price\Range: $0.799
Discount Per Security: $0.05593
Security Name: Common Warrants
Security Type: Equity Warrant
Transaction Features: Registered Direct Offering New Risk • Sep 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.34m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.34m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Aankondiging • Sep 05
Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024 Universe Pharmaceuticals INC, Annual General Meeting, Sep 27, 2024, at 10:00 China Standard Time. Location: 265 jingjiu avenue, jinggangshan economy and, technology development zone, jiangxi 343100, jian city, China New Risk • Aug 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$89.1m market cap). New Risk • Jul 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 53% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$58.9m market cap). Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Xiao Pang was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Aankondiging • Apr 26
Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million. Universe Pharmaceuticals INC has filed a Follow-on Equity Offering in the amount of $25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: $1.25
Discount Per Security: $0 Reported Earnings • Feb 01
Full year 2023 earnings released: US$1.70 loss per share (vs US$2.41 loss in FY 2022) Full year 2023 results: US$1.70 loss per share (improved from US$2.41 loss in FY 2022). Revenue: US$32.3m (down 20% from FY 2022). Net loss: US$6.16m (loss narrowed 30% from FY 2022). New Risk • Aug 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$5.69m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). New Risk • Jun 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.79m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Market cap is less than US$10m (US$9.79m market cap). New Risk • Jun 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$11.3m market cap). Aankondiging • May 25
Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023 Universe Pharmaceuticals INC, Annual General Meeting, Jul 03, 2023, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue,Jinggangshan Economy and Technology Development Zone , Ji’an City, Jiangxi 343100, the People’s Republic of China Hong Kong China Agenda: To discuss re-elect Gang Lai as a director of the Company to hold office until the next annual general meeting of the Company; to re-elect Lin Yang as a director of the Company; to re-elect Jiawen Pang as a director of the Company; to re-elect Ding Zheng as a director of the Company ; to approve the increase of the Company’ s authorized share capital, effective immediately; and to discuss other matters. Aankondiging • May 06
Universe Pharmaceuticals INC Announces Board Changes Universe Pharmaceuticals INC announced that on April 24, 2023, Mr. David Sherman, the Directors of the Company, notified the Company of his resignation as a director of the Company and the chairman of the audit committee of the board of directors, effective May 2, 2023. On May 3, 2023, the Company’s board of directors appointed Mr. Yongping Yu as a director of the Company and the chairman of the nominating and corporate governance committee of the board of directors. The board of directors also appointed Mr. Ding Zheng, a director of the company and the then chairman of the nominating and corporate governance committee of the board of directors, as the chairman of the audit committee of the board of directors. The appointments intend to fill the vacancy created by Mr. David Sherman’s departure. Mr. Yongping Yu has served as one of the Company’s independent directors since May 2023. Mr. Yongping Yu has served as the General Manager of Zhuhai Qirong Venture Capital Investment Management Co. Ltd. since August 2019, a venture capital company focused on the healthcare industry. Mr. Yongping Yu served as a director and Executive Deputy General Manager of Xinhua Kangmei Health Think Tank Co. Ltd. from May 2017 to July 2019. From July 2015 to May 2017, Mr. Yongping Yu served as the General Manager of the Medical Data Division of Xinhua News Agency’s Big Data Business Department. From July 2014 to July 2015, Mr. Yongping Yu served as the Editor-in-Chief and General Manager of Xinhua Cyber Health, a WeChat official account, at Xinhua News Agency. From February 2011 to July 2014, Mr. Yongping Yu served as the Director of the Development Planning Department and Chief Physician of the Aviation General Hospital. From April 2004 to February 2011, Mr. Yongping Yu served as the Deputy Secretary-General of JiangXi Pharmaceutical Association. Mr. Yu obtained a Bachelor of Medicine degree from Nanchang University in the PRC in 1992 and obtained Bachelor of Arts degree in Chinese language and literature from Tsinghua University in the PRC in 1995. Aankondiging • Jan 31
Universe Pharmaceuticals INC announced delayed 20-F filing On 01/30/2023, Universe Pharmaceuticals INC announced that they will be unable to file their next 20-F by the deadline required by the SEC. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 16% share price gain to US$1.69, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total returns to shareholders of 5.4% over the past year. Aankondiging • Dec 22
Universe Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 Universe Pharmaceuticals INC announced that six varieties of the Company's products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 which was published by Beijing Health Commission on December 12, 2022. The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets. The Catalogue supplements the list of recommended medicine in the Ninth Edition of the National Diagnosis and Treatment Plan. The Catalogue recommends 67 types of traditional Chinese medicine products for six different types ofmedical symptoms, such as fever and sore throat, and recommends 41 varieties of western medicine products for four types of clinical symptoms, such as cough and expectoration. In addition to hospitals, patients can also purchase medicines included in the Catalogue from channels such as retail pharmacies and e-commerce platforms according to their own needs. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 18% share price gain to US$1.76, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 19% over the past year. Aankondiging • Nov 15
Universe Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Universe Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) on November 9, 2022, informing the Company that it has regained compliance with the Nasdaq’s minimum bid price requirement and the matter is closed. On July 15, 2022, the Company was notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rules 5450(a)(1) and 5810(c)(3)(A), and was provided 180 calendar days, or until January 11, 2023 to regain compliance. The Notification Letter the Company received from Nasdaq on November 9, 2022 noted that the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from October 26, 2022 through November 8, 2022. Nasdaq stated that accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1). Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment improved over the past week After last week's 27% share price gain to US$1.05, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 13x in the Pharmaceuticals industry in the US. Total loss to shareholders of 55% over the past year. Aankondiging • Aug 30
Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022 Universe Pharmaceuticals INC, Annual General Meeting, Sep 23, 2022, at 10:00 China Standard Time. Location: 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji'an City Ji'an City China Agenda: To re-elect directors; to approve of the proposed filing of a shelf registration statement on Form F-3 registering the Company's ordinary shares, preferred shares, debt securities, warrants, rights and units of up to $200 million; to re-designate 10,000,000 authorized but unissued ordinary shares of the Company; to adopt a second amended and restated memorandum and articles of association; to authorize board of directors to effect a consolidation of the Company's authorized and issued share capital; to consider subject to approval by the shareholders of the Share Consolidation, and entirely conditional upon the effectiveness of the Share Consolidation, with effect as of the date the Company's board of directors may determine in its sole discretion, the Company adopt a third amended and restated memorandum of association. Reported Earnings • Aug 18
First half 2022 earnings released: EPS: US$0.08 (vs US$0.44 in 1H 2021) First half 2022 results: EPS: US$0.08 (down from US$0.44 in 1H 2021). Revenue: US$24.2m (flat on 1H 2021). Net income: US$1.73m (down 76% from 1H 2021). Profit margin: 7.2% (down from 29% in 1H 2021). Aankondiging • Jul 20
Universe Pharmaceuticals Inc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Universe Pharmaceuticals INC announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on July 15, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from June 1, 2022 to July 14, 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 11, 2023, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the Company's ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by January 11, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 20x in the Pharmaceuticals industry in the US. Reported Earnings • Feb 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.60 (up from US$0.47 in FY 2020). Revenue: US$48.0m (up 56% from FY 2020). Net income: US$11.3m (up 50% from FY 2020). Profit margin: 24% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$1.36, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment deteriorated over the past week After last week's 18% share price decline to US$1.88, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in the US. Reported Earnings • Aug 04
First half 2021 earnings released: EPS US$0.44 (vs US$0.32 in 1H 2020) The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: US$24.3m (up 48% from 1H 2020). Net income: US$7.15m (up 41% from 1H 2020). Profit margin: 29% (down from 31% in 1H 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improved over the past week After last week's 40% share price gain to US$3.83, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in the US. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improved over the past week After last week's 22% share price gain to US$3.70, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in the US. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment deteriorated over the past week After last week's 21% share price decline to US$4.09, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in the US.